ATE126441T1 - Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen. - Google Patents

Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.

Info

Publication number
ATE126441T1
ATE126441T1 AT88900424T AT88900424T ATE126441T1 AT E126441 T1 ATE126441 T1 AT E126441T1 AT 88900424 T AT88900424 T AT 88900424T AT 88900424 T AT88900424 T AT 88900424T AT E126441 T1 ATE126441 T1 AT E126441T1
Authority
AT
Austria
Prior art keywords
pentigetide
ige
treatment
inflammatory diseases
mediated inflammatory
Prior art date
Application number
AT88900424T
Other languages
English (en)
Inventor
Pharmaceuticals Inc Dura
Original Assignee
Dura Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dura Pharma Inc filed Critical Dura Pharma Inc
Application granted granted Critical
Publication of ATE126441T1 publication Critical patent/ATE126441T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT88900424T 1986-12-09 1987-12-09 Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen. ATE126441T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/939,927 US4816449A (en) 1984-08-09 1986-12-09 Immunotherapeutic anti-inflammatory peptide agents

Publications (1)

Publication Number Publication Date
ATE126441T1 true ATE126441T1 (de) 1995-09-15

Family

ID=25473943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88900424T ATE126441T1 (de) 1986-12-09 1987-12-09 Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.

Country Status (8)

Country Link
US (1) US4816449A (de)
EP (1) EP0335901B1 (de)
JP (2) JPH02501573A (de)
AT (1) ATE126441T1 (de)
AU (2) AU1049788A (de)
DE (1) DE3751470T2 (de)
DK (2) DK442788A (de)
WO (2) WO1988004177A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468730A (en) * 1984-08-09 1995-11-21 Dura Pharmaceuticals, Inc. Methods for the treatment of non-IgE-mediated diseases
US5061692A (en) * 1984-08-09 1991-10-29 Immunetech Pharmaceuticals Methods and compositions for the treatment of non-IgE-mediated diseases
GB8905606D0 (en) * 1989-03-11 1989-04-26 Scras Peptides
DK122489D0 (da) * 1989-03-14 1989-03-14 Carlsberg Biotechnology Ltd Fremgangsmaade til fremstilling af pentapeptider samt mellemprodukter til brug ved fremstillingen
US5252464A (en) * 1989-03-14 1993-10-12 Carlsberg Biotechnology Ltd. A/S Process for producing pentapeptides and intermediates for use in the synthesis
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
US5028593A (en) * 1989-08-15 1991-07-02 Board Of Regents, The University Of Texas System Tuftsin analogs
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5223487A (en) * 1989-09-30 1993-06-29 Hitachi Chemical Co., Ltd. Peptides as antiallergic agents
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
US5681555A (en) * 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
DK0510912T3 (da) * 1991-04-24 1998-02-09 Morinaga Milk Industry Co Ltd Antimikrobielt peptid og antimikrobielt middel
GB9211668D0 (en) * 1992-06-02 1992-07-15 Nycomed Bioreg As Peptide compounds
US6177405B1 (en) * 1992-07-22 2001-01-23 Kenji Nishioka Cyclic analogs of tuftsin
US5705481A (en) * 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
IL108031A0 (en) * 1992-12-22 1994-04-12 Procter & Gamble Difluoro pentapeptide derivatives and pharmaceutical compositions containing them
WO1995000543A1 (en) * 1993-06-18 1995-01-05 Curative Technologies, Inc. Anti-inflammatory peptides
GB9320897D0 (en) * 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
GB9509957D0 (en) * 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
EP1049795A1 (de) 1998-01-20 2000-11-08 Myriad Genetics, Inc. Mmsc1, ein mit mmac1 interagierendes protein
JP2002501748A (ja) * 1998-01-31 2002-01-22 ユニバーシティ オブ アーカンソー アレルギー反応を減少させるための方法および試薬
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6767890B1 (en) * 1998-11-18 2004-07-27 Coastside Bio Resources Peptides having anti-cancer and anti-inflammatory activity
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
EP1272213B1 (de) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbielles wirkstoffabgabesystem
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6908899B2 (en) * 2001-08-17 2005-06-21 U.S. Dept. Of Veterans Affairs Pro-inflammatory fibrinopeptide
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
CA2457885A1 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
JP2005508623A (ja) * 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP1562621B1 (de) * 2002-11-20 2009-08-19 Arriva-Prometic Inc. Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20050002876A1 (en) * 2003-05-07 2005-01-06 Yukl Richard L. Oral care methods and products
US20070275871A1 (en) * 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
KR20060088543A (ko) * 2003-09-25 2006-08-04 디엠아이 바이오사이언스 인코포레이티드 앤-아실-엘-아스파틱산을 이용하는 방법 및 제품
EP1568707A1 (de) * 2004-02-26 2005-08-31 Puleva Biotech, S.A. Blutdrucksenkenden Peptiden aus Kaseinhydrolysaten
ATE524493T1 (de) * 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
KR102268883B1 (ko) 2013-03-15 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
CN113677404B (zh) 2019-03-26 2024-03-29 卢卡斯梅耶化妆品公司 聚赖氨酸树枝状聚合物在预防和管理易出现痤疮的皮肤和痤疮皮肤中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065808A (en) * 1975-01-25 1977-12-27 U.S. Philips Corporation Network computer system
DE2602443A1 (de) * 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4392997A (en) * 1981-07-06 1983-07-12 Northwestern University Antigenic peptide compounds
US4814973A (en) * 1983-05-31 1989-03-21 Hillis W Daniel Parallel processor
US4683292A (en) * 1983-08-12 1987-07-28 Immunetech, Inc. Immunotherapeutic polypeptide agents which bind to lymphocyte immunoglobulin FC receptors
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
JPH07120275B2 (ja) * 1983-12-28 1995-12-20 株式会社日立製作所 シミューションプログラム生成方法
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
AU612341B2 (en) 1991-07-11
EP0335901A4 (en) 1990-11-28
DK442788D0 (da) 1988-08-08
DK442688A (da) 1988-10-07
US4816449A (en) 1989-03-28
DE3751470T2 (de) 1996-04-04
EP0335901B1 (de) 1995-08-16
JPH02501066A (ja) 1990-04-12
DK442788A (da) 1988-10-07
JPH02501573A (ja) 1990-05-31
EP0335901A1 (de) 1989-10-11
AU1056788A (en) 1988-06-30
DE3751470D1 (de) 1995-09-21
DK442688D0 (da) 1988-08-08
AU1049788A (en) 1988-06-30
WO1988004178A1 (en) 1988-06-16
WO1988004177A1 (en) 1988-06-16

Similar Documents

Publication Publication Date Title
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE3884622D1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE68909219D1 (de) Behandlung von obesitas.
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE3750934D1 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE3777861D1 (de) Behandlung von gasen.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE3871010D1 (de) Behandlung von unfruchtbarkeit.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE71307T1 (de) Verfahren zur behandlung von kontaktlinsen.
PT77020A (de) Mittel zur behandlung von wunden
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE3885798D1 (de) Proteinhaltiges Polysaccharid zur Behandlung retroviraler Infektionen.
DE3668338D1 (de) Kontinuierliche behandlung von spannungslosem gewebe.
DE3680140D1 (de) Behandlung von parasiterkrankungen.
DE3673017D1 (de) Vorrichtung zur behandlung von gliedmassen.
ATE91889T1 (de) Verfahren zur behandlung von brandwunden.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.
ATE86857T1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee